IBC Content Everywhere MENA to Observe Martyrs’ Day in UAE
As a mark of respect to the UAE government’s recent announcement of a public holiday on 30 November 2015 in honour of Emirati armed forces who have lost their lives defending the sovereignty of the nation, IBC has decided to cancel our IBC Content Everywhere MENA event which was due to take place on 29-30 November 2015.
“MENA is an exciting and growing content market, and IBC looks forward to taking an increasingly active role in developing the bridge between the region and the global industry, building on the success of our inaugural IBC Content Everywhere MENA event which took place earlier this year”, commented Michael Crimp, CEO of IBC, “I would like to take this opportunity to thank our MENA industry partners for their continued support of IBC’s global Content Everywhere project.”
IBC looked to consolidate the programme into a single day and sponsors were largely supportive of the move. IBC also looked for another date but this proved unworkable. Traditionally the UAE government adds further days around national holidays leading to a loss in confirmed delegates; feedback indicates that this trend would continue for Martyrs’ Day.
IBC continues to demonstrate its commitment to the region by announcing dates for its IBC Content Everywhere MENA 2016 event, to be held at the Madinat Jumeirah from 31 October – 2 November 2016. This event will follow the format of the successful January 2015 show and consist of a high quality exhibition and conference featuring local and international speakers.
For more information about IBC Content Everywhere MENA please visit ibcCE.org/MENA
To find out more about exhibiting at IBC Content Everywhere MENA 2016 ibcCE.org/MENAexhibitat
## ENDS ##
Dates for forthcoming events:
8-13 September 2016
IBC Content Everywhere Europe
9-13 September 2016
IBC Content Everywhere MENA
31 October - 2 November 2016
About IBC Content Everywhere
Powered and created by IBC, the IBC Content Everywhere global series of events has been created in response to demand from IBC visitors and exhibitors to help professionals from the broadcast, telecommunications, online and IT sectors size up and seize the new opportunities being created by the explosive growth in the consumption of TV and video content on IP-connected smartphones, tablets and laptops.
IBC Content Everywhere combines a high quality exhibition with features specifically designed to help visitors quickly and efficiently expand their knowledge and understanding of the latest trends, strategies and developments in online TV and video. With dedicated events in Europe and MENA, IBC Content Everywhere covers rich media production, devices, apps, digital marketing, social media, content personalisation, big data, cloud services, second screens, investment and much more.
For more information please go to ibcCE.org
IBC is the premier annual event for professionals engaged in the creation, management and delivery of entertainment and news content worldwide. Attracting 55,000+ attendees from more than 170 countries, IBC combines a highly respected and peer-reviewed conference with an exhibition that showcases more than 1,600 leading suppliers of state of the art electronic media technology and provides unrivalled networking opportunities.
For more information visit ibc.org
IBC Content Everywhere Sales Team:
Project Sales Manager
T +44 (0) 134 2717 459
M +44 (0) 7710 991 595
T +971 (0)5 595 64872
M +971 (0)5 595 64872
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom